In a new study, ONCOblot® detected mesothelioma 4-10 years before clinical symptoms in patients with pleural mesothelioma.

The MorNuCo Laboratories of West Lafayette, Indiana, and their ONCOblot® test recently completed a prospective clinical trial focusing on the early detection of malignant mesothelioma, with the exciting results that the ONCOblot® test identified a molecular marker that is suspicious of mesothelioma 4-10 years.

The Test That Reveals Cancer Sooner

MorNuCo Elated to report these findings with the public, since early detection is widely recognized as the basis of a successful approach to reduce cancer-related deaths.

Malignant mesothelioma is an aggressive form of cancer that develops as a result of exposure to asbestos. The presence of a mesothelioma-specific version of the ENOX2 protein (a recently discovered cancer biomarker) in the blood of asbestos-exposed persons was discovered on average 6.2 years before clinical symptoms using.

ENOX2 protein was found in 10 of 20 (50%) of the examined serum samples from asbestos-exposed individuals, taken as part of a cancer surveillance program. To discover how long ahead of clinical signs ENOX2 protein transcript variants could be detected, we tested for ENOX2 protein in prior-dated serum samples from people.

Two mesothelioma-specific ENOX2 protein transcript variants were discovered in the serum of asbestos-exposed persons 4–10 years prior to clinical diagnosis of malignant mesothelioma, an important indication of progress in the field of cancer detection.

“The conclusion of this trial is a milestone in our research,” Nick Miner, Vice President of Business Development, says. “Although asbestos-induced mesothelioma is a one-of-a-kind example of early detection, we are presently engaged in larger-scale clinical trials to see if the ENOX2 protein.

Although the fight against cancer appears to be an immovable obstacle, new diagnostic tools, such as the ONCOblot Test, are being developed at a steady rate.